Bulletin MADRAC

April 2016

• Welcoming the new MADRAC members (2016-2018)
• Pharmacogenomics in Determining Drug Response
• Azithromycin: Risk of QT Prolongation and DRESS
• Mycophenolate: Important New Information on the Teratogenic Risk
• Prolia® and Xgeva® (denosumab): Clinically Significant Cases of Hypercalcaemia after Cessation of Treatment with Denosumab in Paediatric Patients
• Viekirax® and Exviera®: Not Recommended in Patients with Moderate Hepatic Impairment (Child-Pugh B)
• Xalkori® (crizotinib): Inclusion of a New Warning Regarding Cardiac Failure
• Pharmacists: CPD Points for Quality ADR Reports